<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850626</url>
  </required_header>
  <id_info>
    <org_study_id>cSMS-2018</org_study_id>
    <nct_id>NCT03850626</nct_id>
  </id_info>
  <brief_title>Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients</brief_title>
  <official_title>Validierung Des cSMS in Patienten Mit Allergischer Rhinokonjunktivitis (Baum- Und Gräserpollen, Hausstaubmilben). - Eine NIS Bei Patienten, Die Depigoid® Als Spezifische Immuntherapie Erhalten</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leti Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leti Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CSMS was defined by the European Academy of Allergy and Immunology Taskforce as a&#xD;
      standardised tool to assess clinical effects of allergen-specific immunotherapy (AIT). The&#xD;
      aim of this study is to validate the CSMS as a tool to assess the clinical effects of&#xD;
      Depigoid AIT, so that the CSMS can be used in future studies as a primary endpoint as well as&#xD;
      a comparative parameter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 20% of the general public suffer from seasonal or perennial allergic&#xD;
      rhinoconjunctivitis. The only available curative therapy is AIT. The effectiveness of AIT was&#xD;
      demonstrated in numerous randomized clinical trials but comparability is difficult because of&#xD;
      different primary and secondary endpoints.&#xD;
&#xD;
      To validate the CSMS, adolescent (≥ 12 years) and adult patients will be observed who are&#xD;
      allergic to house dust mites (HDM), tree or grass pollen and who were treated with Depigoid.&#xD;
      Depigoid is a registered (for tree and grass pollen) respective authorized (for HDM)&#xD;
      suspension for injection for the treatment of immediate type allergic diseases. Depigoid&#xD;
      contains depigmented and chemically modified allergen extracts, so called allergoids, derived&#xD;
      from grass pollen, tree pollen or HDM.&#xD;
&#xD;
      Allergy symptoms will be documented over a time period of two years: Either for two&#xD;
      consecutive allergy seasons (for tree and grass pollen allergic patients) or for two&#xD;
      consecutive exposure periods (September-December) for HDM allergic patients. The symptoms (4&#xD;
      nasal and 2 ocular symptoms) and allergy medication intake will be documented on a daily&#xD;
      basis either using the CSMS questionnaire or the especially developed electronic CSMS+ diary&#xD;
      application.&#xD;
&#xD;
      Already validated and established questionnaires will be used to validate the CSMS with&#xD;
      regard to Quality of Life (QoL) and symptom control: the Rhinoconjunctivitis Quality of Life&#xD;
      Questionnaire (RQLQ), Adolescent RQLQ (AdolRQLQ, for patients aged 12-17 years), Asthma&#xD;
      Quality of Life Questionnaire (AQLQ) and AQLQ for patients aged 12 years and older (AQLQ+12),&#xD;
      the Asthma Control Test (ACT), Rhinitis Control Assessment Test (RCAT) and the Visual&#xD;
      Analogue Scale (VAS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2018</start_date>
  <completion_date type="Actual">September 3, 2020</completion_date>
  <primary_completion_date type="Actual">September 3, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cSMS</measure>
    <time_frame>after up to 60 days during allergen exposure period (=pollen season resp. allergen season) in 2 consecutive years</time_frame>
    <description>Combined Symptom and Medication Score</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">168</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>Immunotherapy Trees</arm_group_label>
    <description>Patients allergic to tree pollen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunotherapy Grass</arm_group_label>
    <description>Patients allergic to grass pollen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunotherapy Mites</arm_group_label>
    <description>Patients allergic to HDM</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunotherapy</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Immunotherapy Grass</arm_group_label>
    <arm_group_label>Immunotherapy Mites</arm_group_label>
    <arm_group_label>Immunotherapy Trees</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adults and adolescents suffering from allergic diseases (rhinitis, rhinoconjunctivitis,&#xD;
        with or without concomitant asthma)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Indication of an allergen-specific immunotherapy with Depigoid&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - exclusion criteria according to the SmPC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelika Sager, Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>Medical Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. med Andrea Kienle-Gogolok</name>
      <address>
        <city>Bad Schönborn</city>
        <zip>76869</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergy</keyword>
  <keyword>Rhinoconjuctivitis</keyword>
  <keyword>Combined Symptom and Medication Score</keyword>
  <keyword>Allergic Asthma</keyword>
  <keyword>Pollen</keyword>
  <keyword>Mites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

